NASDAQ:ATRC - AtriCure Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$31.35 +0.66 (+2.15 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$30.69
Today's Range$30.1650 - $31.6050
52-Week Range$14.88 - $36.49
Volume225,417 shs
Average Volume210,765 shs
Market Capitalization$1.24 billion
P/E Ratio-37.77
Dividend YieldN/A
Beta0.16
AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
Previous Symbol
CUSIP04963C20
Phone513-755-4100

Debt

Debt-to-Equity Ratio0.31
Current Ratio2.62
Quick Ratio1.96

Price-To-Earnings

Trailing P/E Ratio-37.77
Forward P/E Ratio-34.83
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.72 million
Price / Sales6.91
Cash FlowN/A
Price / CashN/A
Book Value$4.67 per share
Price / Book6.71

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-10.41%
Return on Equity-16.92%
Return on Assets-9.99%

Miscellaneous

Employees570
Outstanding Shares38,530,000
Market Cap$1.24 billion
OptionableOptionable

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) announced its earnings results on Thursday, November, 1st. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The medical device company earned $49.90 million during the quarter, compared to the consensus estimate of $49.90 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 10.41%. The firm's revenue was up 18.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.22) EPS. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for AtriCure.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY18 earnings guidance on Thursday, November, 1st. The company provided earnings per share guidance of ($0.74)-($0.69) for the period, compared to the Thomson Reuters consensus estimate of ($0.80). The company issued revenue guidance of $198-201 million, compared to the consensus revenue estimate of $197.91 million.

What price target have analysts set for ATRC?

5 analysts have issued 1 year price targets for AtriCure's stock. Their forecasts range from $30.00 to $40.00. On average, they anticipate AtriCure's stock price to reach $35.75 in the next year. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

What are Wall Street analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:
  • 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (11/19/2018)
  • 2. Needham & Company LLC analysts commented, "On 10/3/18, ATRC preannounced 3Q18 revenue that was above consensus as 3Q18 revenue accelerated to 18.6% from 13.5% in 2Q18. We note that ATRC had an easy comp due to last year’s hurricanes; management estimates revenue growth was ~16% adjusting for this. Management raised its 2018 revenue guidance but lowered its adjusted EBITDA guidance. Excluding certain items, gross margin declined Y/Y by 40 bps while operating margin improved Y/Y by 360 bps. We believe recent society guidelines, new products, and surgeon training activities should drive strong growth in the near-term and that CONVERGE could be a significant longer- term tailwind and we reiterate our Buy rating." (11/2/2018)
  • 3. BTIG Research analysts commented, "In Q2, AtriCure reported $51.8M in revenue, ~3% better than our Street- high forecast." (8/2/2018)

Has AtriCure been receiving favorable news coverage?

Media headlines about ATRC stock have been trending somewhat positive on Tuesday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AtriCure earned a news sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.

Are investors shorting AtriCure?

AtriCure saw a drop in short interest in October. As of October 15th, there was short interest totalling 1,488,963 shares, a drop of 26.7% from the September 28th total of 2,031,926 shares. Based on an average daily volume of 469,590 shares, the short-interest ratio is presently 3.2 days. Approximately 4.5% of the company's shares are sold short. View AtriCure's Current Options Chain.

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 47)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 43)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 51)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 40)

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (13.77%), BlackRock Inc. (7.16%), First Light Asset Management LLC (2.52%), Loomis Sayles & Co. L P (2.37%), Neuberger Berman Group LLC (1.91%) and Peregrine Capital Management LLC (1.94%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Peregrine Capital Management LLC, Morgan Stanley, Renaissance Technologies LLC, BlackRock Inc., Macquarie Group Ltd., Neuberger Berman Group LLC and Emerald Advisers Inc. PA. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky, M Andrew Wade and Mark A Collar. View Insider Buying and Selling for AtriCure.

Which institutional investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Fosun International Ltd, GW&K Investment Management LLC, Point72 Asset Management L.P., Man Group plc, Prudential Financial Inc., Assenagon Asset Management S.A., FMR LLC and Quantum Capital Management. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $31.35.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.24 billion and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  596
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel